Ethical considerations in post-market-approval monitoring and regulation of vaccines

Vaccine

Volumn 32, Issue 52, 2014, Pages 7171-7174

  Thompson, Alison ^a   Komparic, Ana ^a   Smith, Maxwell J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ethics; Pharmacoepidemiology; Pharmacovigilance; Vaccines

Indexed keywords

VACCINE;

ARTICLE; DECISION MAKING; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; LAW; MEDICAL ETHICS; PHARMACOEPIDEMIOLOGY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRODUCT SAFETY; PUBLIC HEALTH; RESPONSIBILITY; RISK BENEFIT ANALYSIS; TRUST; ETHICS; HUMAN; IMMUNOLOGY; PREVENTIVE HEALTH SERVICE; PROCEDURES; VACCINATION;

DRUG APPROVAL; HUMANS; IMMUNIZATION PROGRAMS; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION; VACCINES;

EID: 84916207816     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.016     Document Type: Article

References (34)

1. Callréus T. Pharmacovigilance and public health ethics. Pharm Med 2013, 27:157-164.
2. MacPherson C.S., Kenny N.P. The power of principles in a national pharmaceuticals strategy. Healthcare Policy 2009, 4:25-36.
3. Giacomini M., Kenny N., DeJean D. Ethics frameworks in Canadian health policies: foundations, scaffolding, or window dressing?. Health Policy 2008, 58-71.
4. ANZTPA The ANZTPA project 2012, ANZTPA.
5. Arlett P., Portier G., de Lisa R., Blake K., Wathion N., Dogne J-M., et al. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nat Rev Drug Discov 2014, 13:395-397.
6. Health Canada. Lifecycle approach model - health products and food regulatory modernization., 2012. (accessed October 21, 2014). http://www.hc-sc.gc.ca/ahc-asc/activit/strateg/mod/ini/index-eng.php.
7. Institute of Medicine Ethical and scientific issues in studying the safety of approved drugs 2012, The National Academies Press, Washington, DC.
8. Standing Senate Committee on Social Affairs, Science and Technology Prescription pharmaceuticals in Canada: post-approval monitoring of safety and effectiveness 2013, Standing Senate Committee on Social Affairs, Science and Technology, Ottawa.
9. Brown K.F. Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine 2010, 28:4235-4248.
10. Ulmer J.B., Liu M.A. Science and society-vaccines: ethical issues for vaccines and immunization. Nat Rev Immunol 2002, 2:291-296.
11. Verweij M., Dawson A. Ethical principles for collective immunisation programmes. Vaccine 2004, 22:3122-3126.
12. European Medicines Agency European Medicines Agency - about us - what we do 2014, European Medicines Agency.
13. Health Canada. Protecting Canadian from Unsafe Drugs Act (Vanessa's Law) amendments to the Food and Drugs Act, 2013. (accessed October 21, 2014). http://www.hc-sc.gc.ca/dhp-mps/legislation/unsafedrugs-droguesdangereuses-eng.php.
14. Japanese Ministry of Health, Labour and Welfare, Japanese Ministry of Health, Labour and Welfare Pharmaceutical affairs law 2005.
15. U.S.Food and Drug Administration Food and Drug Administration Amendments Act (FDAAA) of 2007-FDAAA implementation-highlights two years after enactment 2009, U.S. Food and Drug Administration.
16. Fairchild A.L., Bayer R. Ethics and the conduct of public health surveillance. Science 2004, 303:631-632.
17. Gostin L. Ethical principles for the conduct of human subject research: population-based research and ethics. J Law Med Ethics 1991, 19:191-201.
18. Public Health Ontario A framework for the ethical conduct of public health initiatives 2012, Public Health Ontario, Toronto, ON.
19. Moodley K., Hardie K., Selgelid M.J., Waldman R.J., Strebel P., Rees H., et al. Ethical considerations for vaccination programmes in acute humanitarian emergencies. World Health Organ Bull World Health Organ 2013, 91:290-297.
20. Thompson A., Faith K., Gibson J., Upshur R. Pandemic influenza preparedness: an ethical framework to guide decision-making. BMC Med Ethics 2006, 7:12.
21. Upshur R. Principles for the justification of public health intervention. CJPH 2002, 93:101-103.
22. Lippman A., Melnychuk R., Shimmin C., Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ Can Med Assoc J 2007, 177:484-487.
23. Lennon D., Jackson C., Wong S., Horsfall M., Stewart J., Reid S. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis Off Publ Infect Dis Soc Am 2009, 49:597-605.
24. Thompson A. Human papilloma virus, vaccination and social justice: an analysis of a Canadian school-based vaccine program. Public Health Ethics 2013, 6:11-20.
25. Gerhardus A., Razum O. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. J Epidemiol Community Health 2010, 64:377-378.
26. Ferris L.E., Lemmens T. Governance of conflicts of interest in postmarketing surveillance research and the Canadian drug safety and effectiveness network. Open Med 2010, 4:e123-e128.
27. Lemmens T., Bouchard R. Regulation of pharmaceuticals in Canada. Can. health law policy 2007, 318-387. Butterworths, Toronto, ON. 3rd ed.
28. Blume S.S. Medical innovations: their diffusion, adoption, and critical interrogation. Sociol Compass 2013, 7:726-737.
29. Weir E., Schabas R., Wilson K., Mackie C. A Canadian framework for applying the precautionary principle to public health issues. Can J Public Health Rev Can Santé Publique 2010, 101:396-398.
30. Commission of the European Communities Communication from the commission on the precautionary principle 2000, Commission of the European Communities, Brussels.
31. WHO Outbreak communications planning guide 2008, World Health Organziation, Geneva.
32. O'Malley P., Rainford J., Thompson A. Transparency during public health emergencies: from rhetoric to reality. Bull World Health Organ 2009, 87:614-618.
33. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15:1130-1132.
34. Brown B., Blas M.M., Heidari O., Carcamo C., Halsey N.A. Reported changes in sexual behaviour and human papillomavirus knowledge in Peruvian female sex workers following participation in a human papillomavirus vaccine trial. Int J STD AIDS 2013, 24:531-535.